Publicaciones en colaboración con investigadores/as de Hospital Universitario de Salamanca (125)

2024

  1. Innovative cellular therapies for autoimmune diseases: expert-based position statement and clinical practice recommendations from the EBMT practice harmonization and guidelines committee

    eClinicalMedicine, Vol. 69

2023

  1. Autologous mesenchymal stem cell transplantation for spinal fusion: 10 years follow-up of a phase I/II clinical trial

    Stem cell research & therapy, Vol. 14, Núm. 1, pp. 78

  2. Autologous mesenchymal stromal cells embedded with Tissucol Duo® for prevention of air leak after anatomical lung resection: results of a prospective phase I/II clinical trial with long-term follow-up

    Stem Cell Research and Therapy, Vol. 14, Núm. 1

  3. Cell and gene therapy workforce development: the role of the International Society for Cell & Gene Therapy (ISCT) in the creation of a sustainable and skilled workforce in Europe

    Cytotherapy, Vol. 25, Núm. 10, pp. 1033-1036

  4. Effects of Dietary Supplementation with a Ferulic Acid-Rich Bioactive Component of Wheat Bran in a Murine Model of Graft-Versus-Host Disease

    Nutrients, Vol. 15, Núm. 21

  5. Long-Term Results of a Phase I/II Clinical Trial of Autologous Mesenchymal Stem Cell Therapy for Femoral Head Osteonecrosis

    Journal of Clinical Medicine, Vol. 12, Núm. 6

  6. Uncovering perturbations in human hematopoiesis associated with healthy aging and myeloid malignancies at single-cell resolution

    eLife, Vol. 12

2022

  1. A Systems Biology- and Machine Learning-Based Study to Unravel Potential Therapeutic Mechanisms of Midostaurin as a Multitarget Therapy on FLT3-Mutated AML

    BioMedInformatics, Vol. 2, Núm. 3, pp. 375-397

  2. CT-169 Cytokine Release Syndrome After Peripheral Blood Haploidentical Stem Cell Transplantation With Post-Transplant Cyclophosphamide: Time of Onset Matters

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, pp. S437-S438

  3. CT-195 Predictive Value of ST2, REG3a, and MAGIC Algorithm in Haploidentical Transplantation With Post-Transplant Cyclophosphamide Outcomes

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, pp. S438

  4. Comparison of Outcomes after Unrelated Double-Unit Cord Blood and Haploidentical Peripheral Blood Stem Cell Transplantation in Adults with Acute Myelogenous Leukemia: A Study on Behalf of Eurocord and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

    Transplantation and Cellular Therapy, Vol. 28, Núm. 10, pp. 710.e1-710.e10

  5. Eltrombopag increases the hematopoietic supporting ability of mesenchymal stem/stromal cells

    Therapeutic Advances in Hematology, Vol. 13

  6. External evaluation of population pharmacokinetic models of imatinib in adults diagnosed with chronic myeloid leukaemia

    British Journal of Clinical Pharmacology, Vol. 88, Núm. 4, pp. 1913-1924

  7. Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)

    Annals of Oncology, Vol. 33, Núm. 3, pp. 259-275

  8. Mesenchymal Stromal Cells Combined With Elastin-Like Recombinamers Increase Angiogenesis In Vivo After Hindlimb Ischemia

    Frontiers in Bioengineering and Biotechnology, Vol. 10

  9. Optimization of Mesenchymal Stromal Cell (MSC) Manufacturing Processes for a Better Therapeutic Outcome

    Frontiers in Immunology, Vol. 13

  10. The transcription factor DDIT3 is a potential driver of dyserythropoiesis in myelodysplastic syndromes

    Nature Communications, Vol. 13, Núm. 1

2021

  1. CRISPR-Cas9 Technology as a Tool to Target Gene Drivers in Cancer: Proof of Concept and New Opportunities to Treat Chronic Myeloid Leukemia

    CRISPR Journal, Vol. 4, Núm. 4, pp. 519-535

  2. Co-administration of human MSC overexpressing HIF-1α increases human CD34+ cell engraftment in vivo

    Stem Cell Research and Therapy, Vol. 12, Núm. 1

  3. Efficacy and safety of intramuscular administration of allogeneic adipose tissue derived and expanded mesenchymal stromal cells in diabetic patients with critical limb ischemia with no possibility of revascularization: study protocol for a randomized controlled double-blind phase II clinical trial (The NOMA Trial)

    Trials, Vol. 22, Núm. 1